Canaan Partners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Canaan Partners/Activity

Canaan Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Exit

Accenture acquired a majority stake in Dragos for $3.2B. Canaan was an early investor in the industrial cybersecurity company.

Dragos

Dragos Canaan Partners

canaan.comJUN 18, 2026

JUN 18, 2026

Investment

Co-led Vedana Therapeutics' $46M Series A alongside Westlake BioPartners. Vedana is developing anti-PACAP therapies for migraine prevention.

Vedana Therapeutics

Vedana Therapeutics Canaan Partners

canaan.comJUN 16, 2026

JUN 16, 2026

Essay

Published thesis on B2B agentic payment systems as an emerging opportunity.

B2B Agentic Payments: The Unglamorous Opportunity That Actually Matters

Canaan Partners

Added recently

Exit

Portfolio company Halda Therapeutics acquired by Johnson & Johnson for $3.05B.

Halda Therapeutics

Halda TherapeuticsCanaan Partners

Added recently

Investment

Led OpenArt's $30M Series A round for AI-native visual creativity platform.

OpenArt

OpenArt Canaan Partners

Added recently

Essay

Essay exploring how AI agents are automating core business functions and the importance of early adoption.

Agent Economy: Darwin Is Running Your Next Board Meeting

Canaan Partners

Added recently

Essay

Essay on how AI is collapsing barriers to custom software development for domain experts.

A Message to You, Rudie

Canaan Partners

Added recently

Milestone

Rondo Therapeutics dosed first patient in Phase 1 trial for bispecific antibody RNDO-564.

Rondo Therapeutics

Rondo Therapeutics Canaan Partners

Added recently

Milestone

Hermeus completed first flight of Quarterhorse Mk 2.1 hypersonic aircraft.

Hermeus

Hermeus Canaan Partners

canaan.comAPR 2026

APR 2026

Investment

Led OpenArt's $30M Series A for creative AI tools.

OpenArt

OpenArt Canaan Partners

canaan.comDEC 2025

DEC 2025

Exit

Portfolio company Halda Therapeutics acquired by Johnson & Johnson for $3.05B.

Halda Therapeutics

Halda TherapeuticsCanaan Partners

ventures.yale.eduNOV 17, 2025

NOV 17, 2025

3 investments· FEB 2025 – JUN 2025Show all

Investment

Canaan company Draig Therapeutics launched with $140M Series A to develop next-generation neuropsychiatric medicines targeting glutamate and GABA pathways for major depressive disorder.

Draig Therapeutics

Draig Therapeutics Canaan Partners

canaan.comJUN 18, 2025

JUN 18, 2025

Investment

Participated in Vima Therapeutics' $60M Series A alongside Atlas Ventures and Access Industries. Vima is developing the first oral therapy for dystonia and related movement disorders.

Vima Therapeutics

Vima Therapeutics Canaan Partners

canaan.comMAY 29, 2025

MAY 29, 2025

Investment

Led Valid's seed round. Valid is an AI-powered ad agency reinventing how ads are created, optimized, and deployed.

Valid

Valid Canaan Partners

canaan.comFEB 18, 2025

FEB 18, 2025